The Three-year Underlying Earnings Growth at CK Life Sciences Int'l. (Holdings) (HKG:775) Is Promising, but the Shareholders Are Still in the Red Over That Time
The Three-year Underlying Earnings Growth at CK Life Sciences Int'l. (Holdings) (HKG:775) Is Promising, but the Shareholders Are Still in the Red Over That Time
You can invest in an index fund if you want to make sure your returns approximately match the overall market. But in any given year a good portion of stocks will fall short of that. Unfortunately for investors in CK Life Sciences Int'l., (Holdings) Inc. (HKG:775), the share price has slipped 39% in three years, falling short of the marketdecline of 32%. The more recent news is of little comfort, with the share price down 35% in a year. The falls have accelerated recently, with the share price down 25% in the last three months.
如果你想確保你的回報與整個市場大致相匹配,你可以投資指數基金。但是在任何一年中,很大一部分股票都將低於這個水平。不幸的是,對於長江生命科學國際(控股)有限公司(HKG: 775)的投資者來說,股價在三年內下跌了39%,低於32%的市場跌幅。最近的消息並不令人欣慰,股價在一年內下跌了35%。最近跌勢加速,股價在過去三個月中下跌了25%。
Since CK Life Sciences Int'l. (Holdings) has shed HK$481m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.
自從CK生命科學國際公司開始(Holdings)在過去7天中已從其價值下跌了4.81億港元,讓我們看看長期下跌是否是由該企業的經濟推動的。
There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
不可否認,市場有時是有效的,但價格並不總是能反映潛在的業務表現。研究市場情緒如何隨着時間的推移而變化的一種方法是研究公司股價與其每股收益(EPS)之間的相互作用。
Although the share price is down over three years, CK Life Sciences Int'l. (Holdings) actually managed to grow EPS by 1.9% per year in that time. Given the share price reaction, one might suspect that EPS is not a good guide to the business performance during the period (perhaps due to a one-off loss or gain). Or else the company was over-hyped in the past, and so its growth has disappointed.
儘管股價在三年內下跌,但CK生命科學國際。在那段時間裏,(控股)實際上每年設法將每股收益增長1.9%。鑑於股價的反應,人們可能會懷疑每股收益並不能很好地指導該期間的業務表現(可能是由於一次性的虧損或收益)。否則,該公司過去曾被過度炒作,因此其增長令人失望。
After considering the numbers, we'd posit that the the market had higher expectations of EPS growth, three years back. However, taking a look at other business metrics might shed a bit more light on the share price action.
在考慮了這些數字之後,我們認爲三年前市場對每股收益增長的預期更高。但是,查看其他業務指標可能會進一步了解股價走勢。
With a rather small yield of just 1.5% we doubt that the stock's share price is based on its dividend. We note that, in three years, revenue has actually grown at a 3.3% annual rate, so that doesn't seem to be a reason to sell shares. This analysis is just perfunctory, but it might be worth researching CK Life Sciences Int'l. (Holdings) more closely, as sometimes stocks fall unfairly. This could present an opportunity.
由於收益率相當低,僅爲1.5%,我們懷疑該股的股價是否基於其股息。我們注意到,在三年內,收入實際上以3.3%的年增長率增長,因此這似乎不是出售股票的理由。這種分析只是敷衍了事,但可能值得研究CK Life Sciences Int'l。(持股)更緊密,因爲有時股票會不公平地下跌。這可能帶來機會。
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
您可以在下圖中看到收入和收入隨時間推移而發生的變化(點擊圖表查看確切值)。
If you are thinking of buying or selling CK Life Sciences Int'l. (Holdings) stock, you should check out this FREE detailed report on its balance sheet.
如果你正在考慮買入或賣出CK Life Sciences Internat'l.(控股)股票,您應該在其資產負債表上查看這份免費的詳細報告。
What About Dividends?
分紅呢?
As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. As it happens, CK Life Sciences Int'l. (Holdings)'s TSR for the last 3 years was -37%, which exceeds the share price return mentioned earlier. And there's no prize for guessing that the dividend payments largely explain the divergence!
除了衡量股價回報率外,投資者還應考慮股東總回報率(TSR)。基於股息再投資的假設,股東總回報率納入了任何分拆或貼現資本籌集的價值以及任何股息。因此,對於支付豐厚股息的公司來說,股東總回報率通常遠高於股價回報率。碰巧的是,CK Life Sciences Internat'l。(Holdings)過去3年的股東總回報率爲-37%,超過了前面提到的股價回報率。而且,猜測股息支付在很大程度上解釋了這種分歧是沒有好處的!
A Different Perspective
不同的視角
While the broader market lost about 20% in the twelve months, CK Life Sciences Int'l. (Holdings) shareholders did even worse, losing 35% (even including dividends). However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. On the bright side, long term shareholders have made money, with a gain of 6% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with CK Life Sciences Int'l. (Holdings) (at least 2 which make us uncomfortable) , and understanding them should be part of your investment process.
儘管整個市場在十二個月中下跌了約20%,但CK生命科學國際。(控股)股東的表現甚至更糟,虧損了35%(甚至包括股息)。但是,可能只是股價受到了更廣泛的市場緊張情緒的影響。如果有很好的機會,可能值得關注基本面。好的一面是,長期股東賺了錢,在過去的五年中,每年增長6%。如果基本面數據繼續顯示長期可持續增長,那麼當前的拋售可能是一個值得考慮的機會。我發現將長期股價視爲業務績效的代表非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,投資風險的幽靈無處不在。我們已經向CK Life Sciences Internat'l確定了3個警告信號。(持股)(至少有2筆讓我們感到不舒服),了解它們應該是您投資過程的一部分。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.
當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,請看一下我們預計收益將增加的這份免費公司名單。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.
請注意,本文引用的市場回報反映了目前在香港交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。